ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Sumitomo Dainippon eyes higher psychiatric drug sales in China

Japanese pharma to sharply increase sales reps to pave the way

OSAKA -- Sumitomo Dainippon Pharma will more than triple its medical representatives for psychiatric medications in China to about 100 people by 2022 to help ramp up sales amid expected growth in demand.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more